• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue?

作者信息

Van Wyngaarden K, McDougall I R

机构信息

University of Leiden, The Netherlands.

出版信息

Thyroid. 1997 Jun;7(3):343-6. doi: 10.1089/thy.1997.7.343.

DOI:10.1089/thy.1997.7.343
PMID:9226201
Abstract

Serum thyroglobulin has been measured sequentially in 47 patients with differentiated thyroid cancer who had been treated by surgery and I-thyroxine, but no radioiodine (131I). In 39 of the patients, the operation was subtotal or total thyroidectomy, and in 8 patients it was lobectomy, or lobectomy plus isthmusectomy. In the first group of patients, serum thyroglobulin (Tg) was consistently undetectable in 62% and less than 5 ng/mL in 85%. In the latter group only 1 patient had undetectable Tg values and 2 (25%) had values less than 5 ng/mL. Even in those with higher Tg values, the levels remained constant within a narrow range, provided thyrotropin (TSH) was not high. Serum Tg can be used in conjunction with clinical evaluation in follow-up of patients with differentiated thyroid cancer who have had an operation consisting of more than lobectomy and isthmusectomy and have not been treated with 131I. Its use in patients with lesser operations has to be interpreted in relation to the amount of thyroid left and to the consistency of the results with time.

摘要

相似文献

1
Is serum thyroglobulin a useful marker for thyroid cancer in patients who have not had ablation of residual thyroid tissue?
Thyroid. 1997 Jun;7(3):343-6. doi: 10.1089/thy.1997.7.343.
2
Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.血清甲状腺球蛋白在分化型甲状腺癌治疗后患者随访中的应用
J Clin Endocrinol Metab. 1994 Jul;79(1):98-105. doi: 10.1210/jcem.79.1.8027262.
3
The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.在全甲状腺切除和放射性碘消融治疗后甲状腺癌分化型患者中,抗甲状腺球蛋白抗体阳性且甲状腺功能正常的患者随访期间血清促甲状腺激素升高时,诊断性全身扫描和血清甲状腺球蛋白的价值。
Thyroid. 2012 Feb;22(2):113-6. doi: 10.1089/thy.2011.0020. Epub 2012 Jan 6.
4
Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.分化型甲状腺癌患者甲状腺切除术后残余组织的甲状腺球蛋白及 131I 摄取情况。
Nucl Med Commun. 1988 Apr;9(4):262-6.
5
Undetectable serum thyroglobulin levels in patients with medullary thyroid carcinoma after total thyroidectomy without radioiodine ablation.甲状腺髓样癌患者全甲状腺切除术后未行放射性碘消融时血清甲状腺球蛋白水平不可检测。
Thyroid. 2012 Jul;22(7):680-2. doi: 10.1089/thy.2011.0508. Epub 2012 Jun 4.
6
Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?使用重组人促甲状腺素进行诊断性碘-131扫描对甲状腺切除术后分化型甲状腺癌的随访是否有用?
J Clin Endocrinol Metab. 2002 Apr;87(4):1490-8. doi: 10.1210/jcem.87.4.8338.
7
Follow-up of differentiated thyroid carcinoma.分化型甲状腺癌的随访
Minerva Endocrinol. 2004 Dec;29(4):161-74.
8
Value of repeat stimulated thyroglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the first year after ablation.分化型甲状腺癌患者消融治疗后 1 年内无病状态下重复刺激甲状腺球蛋白检测的价值。
Thyroid. 2012 May;22(5):482-6. doi: 10.1089/thy.2011.0214. Epub 2011 Dec 16.
9
Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.重组人促甲状腺素辅助 131I 消融术前甲状腺球蛋白测定在检测分化型甲状腺癌转移灶中的应用
Clin Endocrinol (Oxf). 2008 Oct;69(4):659-63. doi: 10.1111/j.1365-2265.2008.03244.x. Epub 2008 Mar 18.
10
Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.左甲状腺素对分化型甲状腺癌患者甲状腺球蛋白的抑制作用
J Clin Endocrinol Metab. 1999 Dec;84(12):4549-53. doi: 10.1210/jcem.84.12.6190.

引用本文的文献

1
Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis.低风险和中风险甲状腺癌随访的数据驱动甲状腺球蛋白临界值:ITCO真实世界分析
J Clin Endocrinol Metab. 2025 Apr 22;110(5):e1377-e1384. doi: 10.1210/clinem/dgae559.
2
Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis.低危分化型甲状腺癌的当前争议:在过度诊断时代减少过度治疗。
J Clin Endocrinol Metab. 2023 Jan 17;108(2):271-280. doi: 10.1210/clinem/dgac646.
3
Serum Thyroglobulin Measurement Following Surgery Without Radioactive Iodine for Differentiated Thyroid Cancer: A Systematic Review.
术后未行放射性碘治疗分化型甲状腺癌时的血清甲状腺球蛋白测量:一项系统评价。
Thyroid. 2022 Jun;32(6):613-639. doi: 10.1089/thy.2021.0666. Epub 2022 May 10.
4
Prognostic Impact of Direct I Therapy After Detection of Biochemical Recurrence in Intermediate or High-Risk Differentiated Thyroid Cancer: A Retrospective Cohort Study.中高危分化型甲状腺癌生化复发检测后直接碘治疗的预后影响:一项回顾性队列研究
Front Endocrinol (Lausanne). 2019 Oct 29;10:737. doi: 10.3389/fendo.2019.00737. eCollection 2019.